DelveInsight's HER2+ Gastric Cancer (including GEJ) Market report includes a comprehensive understanding of current treatment practices, emerging HER2+ gastric cancer therapies, market share of ...

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

The FDA has granted traditional approval to Keytruda (pembrolizumab) in combination with trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma.

HER2-mutation testing turnaround time varies, and interpreting results can be complex, requiring clear guidelines and expert input.

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive results and favorable safety.

We identified GPRC5A and TPBG as potential biomarkers for a poor response to anti-HER2 therapy.” “Our proteogenomic analysis of CALGB 40601 revealed likely false-positives among patients diagnosed ...

The phase 3 VERITAC-2 trial, a significant PFS improvement with vepdegestrant was seen in patients with ER+/HER2- advanced breast cancer with ESR1 mutations.

RemeGen's China readout bodes well for Pfizer’s own global phase 3 trial that pairs disitamab vedotin with Keytruda in in first-line bladder cancer.

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d'Hebron ...

Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a manageable safety profile.

Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced today that the US Food ...